Ameriprise
TERN

Ameriprise’s Terns Pharmaceuticals TERN Stock Holding History

Ameriprise’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.23M Sell
118,246
-1,776,135
-94% -$73M ﹤0.01% 2295
2025
Q4 		$76.5M Buy
+1,894,381
New +$43.8M 0.02% 667
2025
Q2 		– Sell
-19,166
Closed -$52.9K – 4124
2025
Q1 		$52.9K Buy
+19,166
New +$78.3K ﹤0.01% 3938

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Ameriprise's TERN Position: Q1 2026 in Review

Ameriprise reduced its Terns Pharmaceuticals (TERN) stake by 94% in Q1 2026, selling an estimated $73M and leaving 118,246 shares worth $6.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2295.

Ameriprise first reported a position in TERN in Q1 2025 and has held it in 3 quarters since. The position peaked at $76.5M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Ameriprise held 118,246 shares of Terns Pharmaceuticals worth $6.23M as of Q1 2026.
  • Ameriprise sold 1,776,135 Terns Pharmaceuticals shares in Q1 2026, an estimated $73M.
  • Terns Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2295 holding.
  • Ameriprise first reported a position in Terns Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Ameriprise's Terns Pharmaceuticals position peaked at $76.5M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.